碳青霉烯类抗生素市场－全球产业规模、份额、趋势、机会及预测，依药物类别、应用、配销通路、地区及竞争格局划分，2020-2030年预测

2024年全球碳青霉烯类抗生素市场规模为39.2亿美元，预计2030年将以4.85%的复合年增长率成长至52.1亿美元。碳青霉烯类抗生素是一类重要的广效β-内酰胺类抗生素，主要用于治疗严重的细菌感染，特别是多重抗药性病原体引起的感染。市场扩张的根本驱动力是日益严峻的全球抗菌素抗药性挑战，这使得人们迫切需要针对复杂感染的有效最后一道防线治疗方案。

主要市场驱动因素

抗菌素抗药性日益严峻的挑战，大大推动了全球碳青霉烯类药物市场的发展。随着病原体发展出逃避传统疗法的机制，碳青霉烯类药物作为最后的治疗手段，变得不可或缺。

主要市场挑战

新型抗生素研发管线的萎缩严重阻碍了全球碳青霉烯类抗生素市场的成长。由于致病菌不断进化并对现有疗法产生抗药性，缺乏新型创新碳青霉烯类药物或针对耐碳青霉烯类细菌的有效替代药物，因此直接限制了市场扩张。

主要市场趋势

仿製碳青霉烯类抗生素的日益普及从根本上影响市场动态，提高了这些关键的最后一道防线抗生素的可及性和可负担性。这一趋势使更多患者群体能够获得必要的治疗，尤其是在预算有限的地区。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球碳青霉烯类抗生素市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（美罗培南、亚胺培南、厄他培南）
  • 依应用领域（泌尿道感染、血液感染、肺炎、腹腔内感染、其他）
  • 按配销通路（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美碳青霉烯类药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲碳青霉烯类抗生素市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区碳青霉烯类抗生素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲碳青霉烯类药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲碳青霉烯类抗生素市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球碳青霉烯类抗生素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Kopran Limited
• Aurobindo Pharma Limited
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.
• Venus Remedies Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Carbapenem Market, valued at USD 3.92 Billion in 2024, is projected to experience a CAGR of 4.85% to reach USD 5.21 Billion by 2030. Carbapenems are a critical class of broad-spectrum beta-lactam antibiotics, primarily reserved for treating severe bacterial infections, particularly those caused by multidrug-resistant pathogens. The market's expansion is fundamentally driven by the escalating global challenge of antimicrobial resistance, necessitating effective last-resort treatments for complex infections.

Key Market Drivers

The escalating challenge of antimicrobial resistance represents a profound impetus for the global carbapenem market. As pathogens develop mechanisms to evade conventional treatments, carbapenems, often serving as last-line therapies, become indispensable. This urgent need is dramatically underscored by the concerning rise in highly resistant organisms; according to the Centers for Disease Control and Prevention, in September 2025, a report in Annals of Internal Medicine revealed NDM-producing carbapenem-resistant Enterobacterales infections surged by more than 460% in the United States between 2019 and 2023.

Key Market Challenges

The diminishing pipeline of novel antibiotics poses a significant impediment to the growth of the Global Carbapenem Market. As bacterial pathogens continuously evolve and develop resistance to existing treatments, the lack of new and innovative carbapenem-class drugs, or alternative agents effective against carbapenem-resistant organisms, directly curtails market expansion. This absence of a robust development pipeline means that the efficacy lifespan of current carbapenems is shortened by the escalating challenge of antimicrobial resistance, leading to a reduced demand as their clinical utility wanes.

Key Market Trends

The increasing penetration of generic carbapenems fundamentally influences market dynamics, improving accessibility and affordability of these critical last-line antibiotics. This trend enables broader patient populations to receive necessary treatments, especially in regions with budget constraints. According to Medicines for Europe, in October 2024, generic medicines constituted 70% of all dispensed medicines in Europe, and over 90% in the United States and India.

Key Market Players

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Kopran Limited
• Aurobindo Pharma Limited
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.
• Venus Remedies Ltd.

Report Scope:

In this report, the Global Carbapenem Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbapenem Market, By Drug Class:

• Meropenem
• Imipenem
• Ertapenem

Carbapenem Market, By Application:

• Urinary Tract Infections
• Blood Stream Infections
• Pneumonia
• Intra-abdominal Infections
• Others

Carbapenem Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Carbapenem Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Carbapenem Market.

Available Customizations:

Global Carbapenem Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carbapenem Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Meropenem, Imipenem, Ertapenem)
  • 5.2.2. By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Carbapenem Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Carbapenem Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Carbapenem Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Carbapenem Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Carbapenem Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Carbapenem Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Carbapenem Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Carbapenem Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Carbapenem Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Carbapenem Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Carbapenem Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Carbapenem Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Carbapenem Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Carbapenem Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Carbapenem Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Carbapenem Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Carbapenem Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Carbapenem Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Carbapenem Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Carbapenem Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Carbapenem Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Carbapenem Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Carbapenem Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Carbapenem Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Carbapenem Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Menarini Group
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Sun Pharmaceutical Industries Ltd
• 15.4. Lupin Limited
• 15.5. Kopran Limited
• 15.6. Aurobindo Pharma Limited
• 15.7. Daewoong Pharmaceuticals Co., Ltd.
• 15.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
• 15.9. Merck & Co., Inc.
• 15.10. Venus Remedies Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer